Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

Tuesday’s trading has closed, but ALXN is being traded in the after-hours session. After-Hours quote »
165.94
Delayed Data
As of 3:59pm ET
 -6.00 / -3.49%
Today’s Change
150.06
Today|||52-Week Range
203.30
-10.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$34.3B

Company Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, transplant rejection and neurology. The company offers Soliris eculizumab, a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria PNH, a blood disorder; and atypical hemolytic uremic syndrome aHUS, an ultra-rare and life-threatening genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult. The company conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; hemolytic uremic syndrome; dense deposit disease; presensitized renal transplant; ABO incompatible renal transplant; myasthenia gravis; neuromyelitis optica; and dry age-related macular degeneration. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. Alexion Pharmaceuticals was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Cheshire, CT.

Contact Information

Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire Connecticut 06410-1138
P:(203) 272-2596
Investor Relations:
(203) 699-7722

Employees

Shareholders

Mutual fund holders65.15%
Other institutional33.56%
Individual stakeholders1.34%

Top Executives

David L. HallalChief Executive Officer & Director
Vikas SinhaChief Financial Officer & Executive Vice President
Martin MacKayExecutive VP, Global Head-Research & Development
Edward MillerChief Compliance Officer & Senior Vice President
Clare M. CarmichaelChief Human Resources Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account